Claybrook Capital, LLC Castle Biosciences Inc Transaction History
Claybrook Capital, LLC
- $172 Million
- Q3 2023
A detailed history of Claybrook Capital, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Claybrook Capital, LLC holds 10,026 shares of CSTL stock, worth $305,191. This represents 0.1% of its overall portfolio holdings.
Number of Shares
10,026
Previous 13,526
25.88%
Holding current value
$305,191
Previous $185,000
8.65%
% of portfolio
0.1%
Previous 0.1%
Shares
5 transactions
Others Institutions Holding CSTL
# of Institutions
202Shares Held
26MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$92.7 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$55.6 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$53.2 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.54MShares$46.8 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$38.4 Million0.61% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $800M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...